Evaluation of prognostic markers in severe drug-induced liver disease

被引:58
作者
Li, Bo [1 ]
Wang, Zhi
Fang, Lian-Jiang
Xu, Ci-Yi
Chen, Wei-Xing
机构
[1] Linuili Hosp, Ningbo Med Ctr, Dept Emergency, Ningbo 315041, Zhejiang, Peoples R China
[2] Ningbo Women & Childrens Hosp, Dept Pediat, Ningbo 315012, Zhejiang, Peoples R China
[3] Ningbo Med Ctr, Lihuili Hosp, Dept ICU, Ningbo 315041, Zhejiang, Peoples R China
[4] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Gastroenterol, Hangzhou 310003, Zhejiang, Peoples R China
关键词
drug-induced liver disease; prognosis; prognostic marker; mortality;
D O I
10.3748/wjg.v13.i4.628
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To analyze the outcome of patients with severe drug-induced liver disease (DILD) associated with jaundice classified as hepatocellular, cholestatic or mixed liver injury and to evaluate the validity of Hy's rule and the most important predictors for outcome. METHODS: The Adverse Drug Reaction Advisory Committee was set up in 1997 in our hospital to identify all suspicions of DILD following a structured prospective report form. Liver damage was divided into hepatocellular, cholestatic, and mixed types according to laboratory and histologic criteria when available. Further evaluation of causality assessment was performed. RESULTS: From January 1997 to December 2004, 265 patients were diagnosed with DILD, and 140 (52.8%) of them were female. hepatocellular damage was the most common (72.1%), the incidence of death was 9.9% in patients with hepatocellular damage and 9.5% in patients with cholestatic/mixed damage (P < 0.05). There was no difference in age of dead and recovered patients. The proportion of females and males was similar in recovered and dead patients, no difference was observed in duration of treatment between the two groups. The serum total bilirubin (P < 0.001), direct bilirubin (P < 0.001) and aspartate transaminase (AST) (P = 0.013) values were higher in dead patients than in recovered patients. Chinese herbal medicine was the most frequently prescribed, accounting for 24.2% of the whole series. However, antitubercular drugs (3.4%) were found to be the primary etiological factor for fetal DILD. Factors associated with the development of fulminant hepatic failure were hepatic encephalopathy (OR = 43.66, 95% CI = 8.47-224.95, P < 0.0001), ascite (OR = 28.48, 95% CI = 9.26-87.58, P < 0.0001), jaundice (OR = 11.43, 95% CI = 1.52-85.96, P = 0.003), alcohol abuse (OR = 3.83, 95% CI = 1.26-11.67, P = 0.035) and direct bilirubin (OR = 1.93, 95% CI = 1.25-2.58, P = 0.012). CONCLUSION: Death occurs in 9.8% of patients with DILD. Chinese herbal medicine stands out as the most common drug for DILD. While antitubercular drugs are found to be the primary etiological factor for fetal DILD, hepatic encephalopathy, ascites, jaundice, alcohol abuse and direct bilirubin levels are associated with the death of DILD patients. (c) 2007 The WJG Press. All rights reserved.
引用
收藏
页码:628 / 632
页数:5
相关论文
共 12 条
[1]
BENICHOU C, 1990, J HEPATOL, V11, P272
[2]
BLACK M, 1975, GASTROENTEROLOGY, V69, P289
[3]
CAUSALITY ASSESSMENT OF ADVERSE REACTIONS TO DRUGS .1. A NOVEL METHOD BASED ON THE CONCLUSIONS OF INTERNATIONAL CONSENSUS MEETINGS - APPLICATION TO DRUG-INDUCED LIVER INJURIES [J].
DANAN, G ;
BENICHOU, C .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1993, 46 (11) :1323-1330
[4]
DAVIDSON CS, 1979, NIH PUBLICATION, V79
[5]
DRUG-INDUCED HEPATIC-INJURY - AN ANALYSIS OF 1100 CASES REPORTED TO THE DANISH-COMMITTEE-ON-ADVERSE-DRUG-REACTIONS BETWEEN 1978 AND 1987 [J].
FRIIS, H ;
ANDREASEN, PB .
JOURNAL OF INTERNAL MEDICINE, 1992, 232 (02) :133-138
[6]
MEDICAL PROGRESS - DRUG-INDUCED HEPATOTOXICITY [J].
LEE, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (17) :1118-1127
[7]
Ohmori S, 2003, HEPATO-GASTROENTEROL, V50, P1531
[8]
Primary care: Evaluation of abnormal liver-enzyme results in asymptomatic patients. [J].
Pratt, DS ;
Kaplan, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (17) :1266-1271
[9]
Senior John R., 2003, P739
[10]
Incidence of drug-induced hepatic injuries: A French population-based study [J].
Sgro, C ;
Clinard, F ;
Ouazir, K ;
Chanay, H ;
Allard, C ;
Guilleminet, C ;
Lenoir, C ;
Lemoine, A ;
Hillon, P .
HEPATOLOGY, 2002, 36 (02) :451-455